|Bid||196.00 x 1000|
|Ask||212.00 x 1400|
|Day's Range||198.09 - 211.91|
|52 Week Range||18.52 - 211.91|
|Beta (5Y Monthly)||0.82|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 23, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||116.25|
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that its Twist Biopharma division has signed two licensing agreements with Serotiny and Applied StemCell. In collaboration with Serotiny, Twist Biopharma aims to discover novel Chimeric Antigen Receptors (CAR) for CAR T-Cell therapies. The agreement with Applied StemCell, covers the use of its TARGATT™ CHO Cell Technology. Both agreements support and expand Twist Biopharma’s capabilities for the discovery of novel antibody therapeutics.
Differences in focus, size of holdings, and weightings add to difficulty in choosing the right fund. Why ARK Genomic Revolution and SPDR S&P Biotech ETFs stand out.